GEN Exclusives

More »

GEN News Highlights

More »
Jul 14, 2010

PPD and Lovelace Biomedical and Environmental Research Institute Partner to Provide Services

  • PPD and Lovelace Biomedical and Environmental Research Institute (LBERI) entered into a collaboration focused on future service opportunities for biopharmaceutical and government clients across a range of therapeutic areas.

    The organizations plan to refer to one another potential business opportunities for laboratory, preclinical, and clinical-development services that they do not offer to their respective clients. In addition, they intend to work together and jointly bid on select new research projects.

    “As demand for preclinical services grows our collaboration with LBERI builds on our strong capabilities and competitive position, particularly in the areas of respiratory, infectious diseases, health outcomes, and epidemiology,” remarks David Grange, CEO of PPD. “This collaboration also enables us to broaden our work with government organizations through LBERI’s existing government relationships.”
    Robert Rubin, Ph.D., president and CEO of Lovelace Respiratory Research Institute, of which LBERI is a subsidiary, adds, “Aligning with one of the world’s leading CROs allows us to build on our 65-plus year history of discovery research, public health advancement, and extensive preclinical service offerings.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »